Kelun-Biotech's final OS analysis of Phase III OptiTROP-Lung04 shows sac-TMT extended median overall survival in lung cancer.
Iza-bren doubled progression-free survival vs chemotherapy in EGFR-mutated NSCLC in the Phase III PANKU LUNG-01 study. Read the full trial results now.
DYNASTY-Breast02 met its primary endpoint for trastuzumab pamirtecan in HER2-low breast cancer, but companies flag limited ...
Researchers built a shark-antibody toxin that kills ERα36 breast cancer cells and shrinks tumors in mice. Human efficacy is unproven. Read the study now.
Roche's sefaxersen met its Phase III IMAgINATION trial endpoint, cutting proteinuria 43.1% vs placebo in IgA nephropathy.
BioNTech and Bristol-Myers Squibb report a 36.7% confirmed response rate for pumitamig in advanced NSCLC after immunotherapy. Read the Phase 2 details now.
Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results